SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. today announced that new research reported by scientists at Stanford University School of Medicine demonstrates a critical role for connective tissue growth factor (CTGF) in the growth of pancreatic cancer tumors. The research showed that tumor growth in mice could be completely prevented by blocking the expression of tumor cell-derived CTGF and that tumor cell survival was compromised under conditions of hypoxic stress in vitro when CTGF levels were low. The findings are supportive of an ongoing phase 1 study of FG-3019, FibroGen’s fully human monoclonal antibody against CTGF, in patients with pancreatic cancer.
